Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Targeted therapies

Sunitinib versus interferon-α in metastatic RCC

Nature Reviews Clinical Oncology volume 7, pages 7–8 (2010)Cite this article

Subjects

Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-α as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Iliopoulos, O. et al. Negative regulation of hypoxia-inducible genes by the von Hippel–Lindau protein. Proc. Natl Acad. Sci. USA 93, 10595–10599 (1996).

    Article  CAS  Google Scholar 

  2. Motzer, R. J. et al. Sunitinib efficacy against advanced renal cell carcinoma. J. Urol. 178, 1883–1887 (2007).

    Article  CAS  Google Scholar 

  3. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).

    Article  CAS  Google Scholar 

  4. Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584–3590 (2009).

    CAS  Google Scholar 

  5. Escudier, B. et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27, 3312–3318 (2009).

    Article  CAS  Google Scholar 

  6. Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 327, 449–456 (2008).

    Article  Google Scholar 

  7. Escudier, B. et al. Bevacizumab plus interferon-α2a for treatment ofmetastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103–2111 (2008).

    Article  Google Scholar 

  8. Rini, B. I. et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26, 5422–5428 (2008).

    Article  CAS  Google Scholar 

  9. Hudes, G. R. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271–2281 (2007).

    Article  CAS  Google Scholar 

  10. Gore, M. E. et al. Safety and efficacy of sunitinib for metastatic renal cell carcinoma: an expanded-access trial. Lancet 10, 757–763 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Massachusetts General Hospital Cancer Center, The Claire and John Bertucci Center for Genitourinary Cancers, 55 Fruit Street, YAW7, Boston, 02114, MA, USA

    Jason E. Faris & M. Dror Michaelson

Authors
  1. Jason E. Faris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Dror Michaelson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Dror Michaelson.

Ethics declarations

Competing interests

M. D. Michaelson declares that he is a consultant for Genentech and is a consultant and on the speakers bureau for Wyeth; he has received grant/research support from Amgen, Genentech, GlaxoSmithKline and Pfizer. J. E. Faris declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Faris, J., Michaelson, M. Sunitinib versus interferon-α in metastatic RCC. Nat Rev Clin Oncol 7, 7–8 (2010). https://doi.org/10.1038/nrclinonc.2009.173

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.173

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing